The le

The amount of formazan dye generated by the activity of mitochondrial dehydrogenases in cells is directly proportional to the number of living cells. CCK8 is more sensitive than the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium

bromide assay [10]. SKOV3 cells were trypsinized and seeded at 5 × 103 cells/well in 96 well plates Napabucasin in vitro in 3D cultures. After 24 h, various concentrations of bevacizumab were added, followed by incubation for another 48 h. Then, 10 μL CCK8 (Sigma, USA) solution in PBS was added to each well. Plates were incubated for an additional 2 h. The optical density of each well was IBET762 measured using a microculture plate reader at a 490 nm wavelength. Statistical analysis All results were evaluated using the SPSS 13.0 statistical software package. Data were analyzed using one-way ANOVA. Results were expressed as the mean ± standard deviation, and P < 0.05 was considered statistically significant. Results Increased metastasis after short-term treatment with the angiogenesis Inhibitor bevacizumab In our study, a model of metastasis was used to

test the effect of short-term bevacizumab treatment. SKOV3LUC+ cells expressing luciferase were directly injected into the tail vein of female nude mice and then received bevacizumab and/or cisplatin treatment for 3 weeks. Forty mice were equally divided into four groups at random (PBS, bevacizumab, CFTRinh-172 ic50 cisplatin and bevacizumab + cisplatin groups). Tumor growth and metastasis were monitored by bioluminescence at 1 and 4 weeks after treatment. Mean photon counts of each group were quantified, and

the ratio of metastasis was measured. The pulmonary metastasis rate was 100%. Tumor growth delay was observed at 1 week after bevacizumab and/or cisplatin treatments, without extrapulmonary Methocarbamol metastasis. Short-term bevacizumab treatment resulted in accelerated extrapulmonary metastasis at 4 weeks after treatment. Extrapulmonary metastases were found in livers and legs. Cisplatin and bevacizumab + cisplatin treatment inhibited tumor growth, compared with that of PBS treatment.. While no significant difference in tumor growth was observed between bevacizumab and control groups (Figure 1). Figure 1 Increased metastasis after short-term treatment with bevacizumab. Forty mice were assigned into four groups (PBS, bevacizumab, cisplatin and bevacizumab + cisplatin). Mean photon counts of each group were quantified. (A) Tumor growth and metastasis were monitored by bioluminescence at 1 and 4 weeks after treatment. A representative experiment is shown. (B) Short-term bevacizumab treatment resulted in accelerated extrapulmonary metastasis at 4 weeks after treatment. Extrapulmonary metastases were found in the livers and legs. The ratio of metastasis of each group was measured.

Comments are closed.